To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

The Alzheimer's Associati… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers.

Journal article
Authors Niklas Mattsson
Ulf Andreasson
Staffan Persson
Hiroyuki Arai
Sat Dev Batish
Sergio Bernardini
Luisella Bocchio-Chiavetto
Marinus A Blankenstein
Maria C Carrillo
Sonia Chalbot
Els Coart
Davide Chiasserini
Neal Cutler
Gunilla Dahlfors
Stefan Duller
Anne M Fagan
Orestes Forlenza
Giovanni B Frisoni
Douglas Galasko
Daniela Galimberti
Harald Hampel
Aase Handberg
Michael T Heneka
Adrianna Z Herskovits
Sanna-Kaisa Herukka
David M Holtzman
Christian Humpel
Bradley T Hyman
Khalid Iqbal
Mathias Jucker
Stephan A Kaeser
Elmar Kaiser
Elisabeth Kapaki
Daniel Kidd
Peter Klivenyi
Cindy S Knudsen
Markus P Kummer
James Lui
Albert Lladó
Piotr Lewczuk
Qiao-Xin Li
Ralph Martins
Colin Masters
John McAuliffe
Marc Mercken
Abhay Moghekar
José Luis Molinuevo
Thomas J Montine
William Nowatzke
Richard O'Brien
Markus Otto
George P Paraskevas
Lucilla Parnetti
Ronald C Petersen
David Prvulovic
Herman P M de Reus
Robert A Rissman
Elio Scarpini
Alessandro Stefani
Hilkka Soininen
Johannes Schröder
Leslie M Shaw
Anders Skinningsrud
Brith Skrogstad
Annette Spreer
Leda Talib
Charlotte Teunissen
John Q Trojanowski
Hayrettin Tumani
Robert M Umek
Bianca Van Broeck
Hugo Vanderstichele
Laszlo Vecsei
Marcel M Verbeek
Manfred Windisch
Jing Zhang
Henrik Zetterberg
Kaj Blennow
Published in Alzheimer's & dementia : the journal of the Alzheimer's Association
Volume 7
Issue 4
Pages 386-395.e6
ISSN 1552-5279
Publication year 2011
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 386-395.e6
Language en
Subject categories Psychiatry


The cerebrospinal fluid (CSF) biomarkers amyloid β (Aβ)-42, total-tau (T-tau), and phosphorylated-tau (P-tau) demonstrate good diagnostic accuracy for Alzheimer's disease (AD). However, there are large variations in biomarker measurements between studies, and between and within laboratories. The Alzheimer's Association has initiated a global quality control program to estimate and monitor variability of measurements, quantify batch-to-batch assay variations, and identify sources of variability. In this article, we present the results from the first two rounds of the program.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?